Sunday, November 22, 2026

FibroGen Stock Bullish Momentum With A 10.53% Rise On Tuesday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

FibroGen Stock Bullish Momentum With A 10.53% Rise On Tuesday

(VIANEWS) - The NASDAQ ended the session with FibroGen (FGEN) jumping 10.53% to $1.89 on Tuesday while NASDAQ rose 1.54% to $16,265.64.

FibroGen's last close was $1.71, 91.82% under its 52-week high of $20.90.

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.

Revenue Growth

Year-on-year quarterly revenue growth declined by 21%, now sitting on 147.75M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FibroGen's EBITDA is 0.64.

Moving Average

FibroGen's value is way higher than its 50-day moving average of $1.52 and way under its 200-day moving average of $3.01.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen's stock is considered to be overbought (>=80).

More news about FibroGen (FGEN).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 12 Mar 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.